Novartis, Johnson & Johnson and Consort Medical all returned to invest in the company's series C round as it looks to commercialise its diagnostic testing system.
UK-based molecular diagnostics technology provider Atlas Genetics, a spin-out of Bath University, has raised $20m in a series C round that included pharmaceutical firms Novartis, Johnson & Johnson and Consort Medical.
Novartis and Johnson & Johnson, which invested through respective corporate venturing units Novartis Venture Funds and Johnson & Johnson Innovation, and Consort were joined by RMI Partners, LSP, BB Biotech Ventures and South West Ventures Fund.
Atlas develops diagnostic tests for infectious diseases based on electrochemical sensor technology. The…
